HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

Livzon Pharmaceutical (000513.CH) - A Good Company that You Can't Afford Missing

Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns

Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy

Edding Group (亿腾医药) Pre-IPO: Distributor Turning Pharmaceutical

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<p style="text-align: justify;"><a href="https://www.smartkarma.com/entities/edding-group-company-limited" target="_blank" data-smartkarma-citation="entities:29731:1" rel="noopener">Edding Group (EDG HK)</a> has filed its prospectus with the Hong Kong Stock Exchange for listing recently. The Company has established a highly differentiated and diversified product portfolio, mainly divided into three categories: anti-infectives, cardiovascular system and respiratory system. The following analyzed both the market potential and concerns for Edding.</p>

Edding Group (EDG HK) has filed its prospectus with the Hong Kong Stock Exchange for listing recently. The Company has established a highly differentiated and diversified product portfolio, mainly divided into three categories: anti-infectives, cardiovascular system and respiratory system. The following analyzed both the market potential and concerns for Edding.

Pre-IPO Edding Group - Strong Core Products but Still Have Concerns